全文获取类型
收费全文 | 1522981篇 |
免费 | 127839篇 |
国内免费 | 4606篇 |
专业分类
耳鼻咽喉 | 24089篇 |
儿科学 | 50543篇 |
妇产科学 | 41842篇 |
基础医学 | 204252篇 |
口腔科学 | 38892篇 |
临床医学 | 143960篇 |
内科学 | 316255篇 |
皮肤病学 | 34838篇 |
神经病学 | 122796篇 |
特种医学 | 59200篇 |
外国民族医学 | 367篇 |
外科学 | 250544篇 |
综合类 | 28231篇 |
现状与发展 | 73篇 |
一般理论 | 450篇 |
预防医学 | 108894篇 |
眼科学 | 35233篇 |
药学 | 106406篇 |
2篇 | |
中国医学 | 2728篇 |
肿瘤学 | 85831篇 |
出版年
2021年 | 12215篇 |
2018年 | 20858篇 |
2017年 | 17418篇 |
2016年 | 19689篇 |
2015年 | 21520篇 |
2014年 | 33506篇 |
2013年 | 43499篇 |
2012年 | 45875篇 |
2011年 | 48794篇 |
2010年 | 35070篇 |
2009年 | 37099篇 |
2008年 | 47229篇 |
2007年 | 49028篇 |
2006年 | 51489篇 |
2005年 | 48237篇 |
2004年 | 45875篇 |
2003年 | 43358篇 |
2002年 | 42775篇 |
2001年 | 62606篇 |
2000年 | 63112篇 |
1999年 | 54717篇 |
1998年 | 18906篇 |
1997年 | 17040篇 |
1996年 | 17040篇 |
1995年 | 16158篇 |
1994年 | 14286篇 |
1993年 | 12967篇 |
1992年 | 42827篇 |
1991年 | 42196篇 |
1990年 | 41319篇 |
1989年 | 40235篇 |
1988年 | 37506篇 |
1987年 | 36588篇 |
1986年 | 34932篇 |
1985年 | 33265篇 |
1984年 | 24958篇 |
1983年 | 21766篇 |
1982年 | 13484篇 |
1979年 | 23248篇 |
1978年 | 16534篇 |
1977年 | 14431篇 |
1976年 | 13460篇 |
1975年 | 14720篇 |
1974年 | 17134篇 |
1973年 | 16519篇 |
1972年 | 15771篇 |
1971年 | 14564篇 |
1970年 | 13555篇 |
1969年 | 12924篇 |
1968年 | 12111篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
F. Fruzzetti G. Palla A. Sbrana T. Simoncini M. R. Sessa 《Gynecological endocrinology》2020,36(10):938-940
AbstractObjective: To understand the origin of extremely high gonadotropin levels in a perimenopausal woman.Methods: A 52-year-old woman with a 2?months of amenorrhea followed spontaneous menstrual cycles recovery was referred to our outpatient clinic with elevated follicle-stimulating hormone (FSH, 483 mUI/ml), luteinizing hormone (LH, 475 mUI/ml) and prolactin (PRL, 173?ng/ml). She was known to take levosulpiride. The gonadotropin levels did not fit with the clinical features.Results: A gonadotroph tumor was ruled out. Further analysis confirmed constantly high FSH, LH and PRL levels. The measurements were repeated using different analytical platforms with different results. After serial dilutions, nonlinearity was present suggesting an immunoassay interference. After post-polyethylene glycol recovery, hormone levels appeared in the normal range. Anti-goat antibodies were recognized in the serum of the patient.Conclusions: This case report shows a case of falsely abnormal high gonadotropin and PRL levels in a woman during menopause transition. In the clinical practice the evaluation of gonadotropin profile is not recommended at this age, but the abnormal levels stimulated further evaluation. An interference in the assay due to anti-goat antibodies resulted in abnormally high level of FSH and LH. A strict collaboration between clinicians and the laboratory is needed, when laboratory findings do not correspond to clinical findings. 相似文献
5.
6.
Stelter K. Theodoraki M. N. Becker S. Tsekmistrenko V. Olzowy B. Ledderose G. 《European archives of oto-rhino-laryngology》2015,272(3):639-639
European Archives of Oto-Rhino-Laryngology - 相似文献
7.
M. Iachina P.M. Ljungdalh R.G. Sørensen L. Kaerlev J. Blaakær O. Trosko N. Qvist B.M. Nørgård 《Clinical oncology (Royal College of Radiologists (Great Britain))》2019,31(2):115-123
Aims
To examine the influence of pre-existing psychiatric disorder on the choice of treatment in patients with gynaecological cancer.Materials and methods
The analyses were based on all patients who underwent surgical treatment for endometrial, ovarian or cervical cancer who were registered in the Danish Gynecological Cancer Database in the years 2007–2014 (3059 patients with ovarian cancer, 5100 patients with endometrial cancer and 1150 with cervical cancer). Logistic regression model and Cox regression model, adjusted for relevant confounders, were used to estimate the effect of pre-existing psychiatric disorder on the course of cancer treatment. Our outcomes were (i) presurgical oncological treatment, (ii) macroradical surgery for patients with ovarian cancer, (iii) radiation/chemotherapy within 30 days and 100 days after surgery and (iv) time from surgery to first oncological treatment.Results
In the group of patients with ovarian cancer, more patients with a psychiatric disorder received macroradical surgery versus patients without a psychiatric disorder, corresponding to an adjusted odds ratio of 1.24 (95% confidence interval 0.62–2.41) and the chance for having oncological treatment within 100 days was odds ratio = 1.26 (95% confidence interval 0.77–2.10). As for patients with endometrial cancer, all outcome estimates were close to unity. The adjusted odds ratio for oncological treatment within 30 days after surgery in patients with cervical cancer with a history of psychiatric disorder was 0.20 (95% confidence interval 0.03–1.54).Conclusions
We did not find any significant differences in the treatment of ovarian and endometrial cancer in patients with pre-existing psychiatric diagnoses. When it comes to oncological treatment, we suggest that increased attention should be paid to patients with cervical cancer having a pre-existing psychiatric diagnosis. 相似文献8.
Srdan Verstovsek MD PhD Jean-Jacques Kiladjian MD PhD Alessandro M. Vannucchi MD Ruben A. Mesa MD FACP Peg Squier MD PhD J. E. Hamer-Maansson MSPH Claire Harrison MD 《Cancer》2023,129(11):1681-1690
Background
In a pooled analysis of the phase 3 Controlled Myelofibrosis Study With Oral JAK Inhibitor Treatment I (COMFORT-I) and COMFORT-II clinical trials, adult patients with intermediate-2 or high-risk myelofibrosis who received oral ruxolitinib at randomization or after crossover from placebo or best available therapy (BAT) had improved overall survival (OS).Methods
This post hoc analysis of pooled COMFORT data examined relevant disease outcomes based on the disease duration (≤12 or >12 months from diagnosis) before ruxolitinib initiation.Results
The analysis included 525 patients (ruxolitinib: ≤12 months, n = 84; >12 months, n = 216; placebo/BAT: ≤12 months, n = 66; >12 months, n = 159); the median age was 65.0–70.0 years. Fewer thrombocytopenia and anemia events were observed among patients who initiated ruxolitinib treatment earlier. At Weeks 24 and 48, the spleen volume response (SVR) was higher for patients who initiated ruxolitinib earlier (47.6% vs. 32.9% at Week 24, p = .0610; 44.0% vs. 26.9% at Week 48, p = .0149). In a multivariable analysis of factors associated with spleen volume reduction, a logistic regression model that controlled for confounding factors found that a significantly greater binary reduction was observed among patients with shorter versus longer disease duration (p = .022). At Week 240, OS was significantly improved among patients who initiated ruxolitinib earlier (63% [95% CI, 51%‒73%] vs. 57% [95% CI, 49%‒64%]; hazard ratio, 1.53; 95% CI, 1.01‒2.31; p = .0430). Regardless of disease duration, a longer OS was observed for patients who received ruxolitinib versus those who received placebo/BAT.Conclusions
These findings suggest that earlier ruxolitinib initiation for adult patients with intermediate-2 and high-risk myelofibrosis may improve clinical outcomes, including fewer cytopenia events, durable SVR, and prolonged OS.Plain Language Summary
- Patients with myelofibrosis, a bone marrow cancer, often do not live as long as the general population. These patients may also have an enlarged spleen and difficult symptoms such as fatigue.
- Two large clinical trials showed that patients treated with the drug ruxolitinib lived longer and had improved symptoms compared to those treated with placebo or other standard treatments.
- Here it was examined whether starting treatment with ruxolitinib earlier (i.e., within a year of diagnosis) provided benefits versus delaying treatment.
- Patients who received ruxolitinib within a year of diagnosis lived longer and experienced fewer disease symptoms than those whose treatment was delayed.
9.
Implications for Practice
Breast cancer is far more curable than in the past but requires multimodality treatment. Great care must be taken to use the least leukemogenic treatment programs that do not sacrifice efficacy. Elimination of radiation and anthracycline/alkylating agent regimens will be helpful where possible, particularly in younger patients and possibly those with homologous repair deficiency (HRD). Use of colony-stimulating factors should be limited to those who truly require them for safe chemotherapy administration. Further study of a possible leukemogenic association with HRD and the various forms of colony-stimulating factors is badly needed.10.